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antigen-targeting region of a monoclonal 
antibody fused to the signaling molecules of 
the T cell receptor and costimulatory mole-
cules.[2] CD19-specific CAR T cells have 
been approved by Food and Drug Adminis-
tration (FDA) to treat B cell malignancies.[3] 
However, the efficacy of CAR T cells against 
solid tumors remains modest mostly 
because of the inefficient infiltration of CAR 
T cells into the tumor and the abundant 
presence of immunosuppressive cells in the 
tumor microenvironment.[4] To exploit their 
effector function, CAR T cells must engage 
chemotactic signals to traffic and accumu-
late into the tumor.[5] The physical barriers 
represented by the extracellular matrix and 
stroma, together with the abnormal tumor 
vasculature and high interstitial fluid pres-
sure (IFP), prevent the adequate infiltration 
of CAR T cells.[6] The development of strate-
gies to promote the infiltration of CAR T cells in solid tumors has 
become one of the major themes in the field.
Photothermal therapy employs optical absorbing agents 
to “burn” tumor cells by effectively generating heat under the 
near-infrared (NIR) light irradiation.[7] Compared to traditional 
cancer therapies, photothermal therapy has unique advantages 
that include high selectivity, low systemic toxicity, and limited 
therapeutic resistance.[8] As shown in Figure 1, we propose that 
poly(lactic-co-glycolic) acid (PLGA) nanoparticles[9] loaded with 
indocyanine green (ICG),[7a,10] an NIR dye used as the photo-
thermal agent, injected intratumorally can promote direct 
tumor cell killing, partial disruption of the extracellular matrix, 
decrease of the IFP, and increase of the blood perfusion.[11] 
Moreover, the destruction of cancer cells by hyperthermia 
causes inflammation, which could enhance recruitment of 
immune cells and secretion of a variety of chemokines and 
cytokines. Working together with the released tumor-specific 
antigens after photothermal ablation, the proposed therapy 
greatly enhances the tumor infiltration and activation of CAR T 
cells and improves efficacy.
PLGA, a polymer applied in formulations approved by the 
US FDA, was used to encapsulate ICG via an oil-in-water (o/w) 
emulsion method. Monodispersed PLGA-ICG nanoparticles 
(≈100 nm) with spherical shape were obtained, as revealed 
by the transmission electron microscopy (TEM) imaging and 
dynamic light scattering (Figure 2a). PLGA-ICG nanoparticles 
exhibited a characteristic absorption peak of ICG at ≈780 nm, 
which is ideal for effective photothermal therapy (Figure 2b). 
Temperature elevation was observed when the PLGA-ICG 
Chimeric antigen receptor (CAR)-redirected T lymphocytes (CAR T cells) show 
modest therapeutic efficacy in solid tumors. The desmoplastic structure of 
the tumor and the immunosuppressive tumor microenvironment usually 
account for the reduced efficacy of CAR T cells in solid tumors. Mild 
hyperthermia of the tumor reduces its compact structure and interstitial 
fluid pressure, increases blood perfusion, releases antigens, and promotes 
the recruitment of endogenous immune cells. Therefore, the combination of 
mild hyperthermia with the adoptive transfer of CAR T cells can potentially 
increase the therapeutic index of these cells in solid tumors. It is found that 
the chondroitin sulfate proteoglycan-4 (CSPG4)-specific CAR T cells infused in 
Nod scid gamma mice engrafted with the human melanoma WM115 cell line 
have superior antitumor activity after photothermal ablation of the tumor. The 
findings suggest that photothermal therapy facilitates the accumulation and 
effector function of CAR T cells within solid tumors.
Photothermal Therapy Promotes Tumor Infiltration 
and Antitumor Activity of CAR T Cells
T cells genetically engineered with chimeric antigen receptor 
(CAR) provide radically innovative and sophisticated methods 
for cancer treatment.[1] CARs are typically composed of the 
Figure 1. Schematic illustration showing the effects of the mild heating of the tumor that causes enhanced infiltration and activation of adoptive 
transfer CAR.CSPG4+ T cells.
Figure 2. Photothermal therapy of the tumor promotes CAR T cell proliferation and cytokine release. a) Hydrodynamic diameter of PLGA-ICG nanoparticles 
measured by dynamic light scattering. The insert is the TEM image of PLGA-ICG (Scale bar: 200 nm). b) The UV–vis–NIR spectrum of PLGA-ICG, exhibiting 
high absorption in the near infrared region. c) IR thermal images and d) temperature curves of PBS and PLGA-ICG under the 808 nm light irradiation for 5 min 
at the power density of 0.5 W cm−2. Data are presented as mean ± s.e.m. (n = 3). e) Representative flow cytometry analysis of CAR.CSPG4+ T cells labeled with 
CFSE three days after the indicated treatments. f) Mean fluorescence intensity of CFSE, indicating T cell proliferation. Data are presented as mean ± s.e.m. 
(n = 4). g,h) Detection of IL-2 (g) and IFN-γ (h) in the supernatant of CAR.CSPG4+ T cells, three days after the indicated treatments. Data are presented as 
mean ± s.e.m. (n = 4). Statistical significance was calculated via one-way ANOVA with a Tukey post hoc test. P value: *P < 0.05, **P < 0.01, and ***P < 0.001.
suspension was irradiated using an 808 nm laser (0.5 W cm−2 
for 5 min), while pure phosphate buffered saline (PBS) solution 
showed modest temperature increase under the same laser irra-
diation (Figure 2c,d; Figure S1, Supporting Information). Con-
focal fluorescent images of propidium iodide (PI) and Calcine 
AM costained cells and the PI and Annexin V staining with 
flow cytometry further confirmed the effective photothermal 
ablation of cancer cells (Figure S2, Supporting Information).
We then investigated whether ex vivo photothermal exposure 
of the tumor cells affects CAR T cell functions. To demonstrate 
this proof of concept, we used CAR T cells targeting the antigen 
chondroitin sulfate proteoglycan-4 (CSPG4) that is overex-
pressed in melanoma and glioblastoma, while limited distribu-
tion is observed in normal tissues.[12] T lymphocytes obtained 
from healthy donors were engineered to express the CSPG4. 
CAR (Figure S3, Supporting Information). We evaluated the 
proliferation of CAR.CSPG4+ T cells using the carboxyfluores-
cein diacetate succinimidyl ester (CFSE)-based assay. The mela-
noma cell line WM115 that expresses CSPG4 with or without 
photothermal exposure, was placed in the upper chamber of a 
transwell with the pore size ≈1 µm and CAR.CSPG4+ T cells 
were seeded in the lower chamber. After three days of culture, 
CSPG4.CAR T cells vigorously proliferated after coculture with 
WM115 cells upon photothermal ablation, suggesting that the 
CSPG4 protein released from WM115 cells after photothermal 
therapy engages and stimulates CSPG4-specific CAR T cells 
(Figure 2e,f). The activation of CSPG4.CAR T cells in response 
to WM115 cells after photothermal ablation was further 
confirmed by the increased production of interleukin-2 (IL-2) 
and interferon-γ (IFN-γ) (Figure 2g,h).
To validate whether the photothermal therapy can enhance 
the antitumor effects of CAR T cells in solid tumors, we first 
characterized the effects of mild photothermal ablation in 
Nod scid gamma (NSG) mice bearing the human melanoma 
WM115 tumor subcutaneously. We injected intratumorally the 
PLGA-ICG nanoparticles and irradiated the tumor with the 
808 nm laser at the power density of 0.3 W cm−2. The tem-
perature associated with the tumor injected with PLGA-ICG 
increased to ≈44 °C within 2 min as monitored by an infrared 
thermal camera (Figure 3a,b). After the photothermal treat-
ment, the morphology of the tumor vasculature appeared 
dilated with reduced IFP as compared to control tumors 
(Figure 3c). Increased ultrasonic signal was also recorded 24 h  
after the photothermal ablation by ultrasound imaging with 
a microbubble contrast agent, further suggesting an increase 
in tumor perfusion (Figure 3d). Moreover, the signals of the 
hypoxia probe pimonidazole and the hypoxia-inducible factor 
(HIF)-1α were decreased, suggesting enhanced oxygenation 
(Figure 3e). Finally, photothermal ablation caused the intra-
tumor increase of murine monocytes (CD45+CD11b+) and 
dendritic cells (CD45+CD11c+) (Figure 3f–h) as well as murine 
chemokines such as chemokine ligand 5 (CCL5), CCL11, 
chemokine (C-X-C motif) ligand 1 (CXCL1), CCL2, CCL3, and 
CCL4 (Figure 3i).
Next, a xenograft model of melanoma was established by 
inoculating WM115 tumor cells into both flanks of NSG mice. 
After three weeks, the tumors in the right flank were intra-
tumorally injected with PLGA-ICG and irradiated with the 
808 nm laser. Two hours later, 1 × 107 CAR.CSPG4+ T cells 
or CAR.CD19+ T cells labeled with the firefly luciferase were 
intravenously injected. T cell biodistribution was monitored by 
in vivo imaging system (IVIS) at different time points after CAR 
T cell administration. Increased localization of CAR.CSPG4+ T 
cells was observed in tumors that received photothermal therapy 
as compared to the contralateral tumors (Figure S4, Supporting 
Information; Figure 4a,b). Flow cytometry (Figure 4c–f) and 
immunofluorescence imaging (Figure 4g) confirmed the accu-
mulation of CAR.CSPG4+ T cells in the tumors treated with 
photothermal therapy.
To assess the antitumor activity of combining photothermal 
therapy and CAR.CSPG4+ T cells, we labeled the WM115 human 
melanoma tumor cell line with firefly luciferase. WM115 tumor 
bearing mice were intratumorally injected with PLGA-ICG and 
irradiated with the 808 nm laser for 20 min at a power density 
of 0.3 W cm−2. Two hours later, 1 × 107 CAR.CSPG4+ T cells 
were intravenously injected into the mice. Tumor growth was 
monitored using both in vivo bioluminescence (Figure 5a) 
and caliper measurement (Figure 5b,c). Photothermal therapy 
combined with CAR.CSPG4+ T cells significantly suppressed 
the tumor growth up to 20 days as compared with control 
groups. Two out of six mice receiving the combined treatment 
were macroscopically tumor free at the end of the experiment 
as confirmed by immunohistochemistry and terminal deoxy-
nucleotidyl transferase-mediated dUTP-biotin nick end labe-
ling assay (Figures S5 and S6, Supporting Information). In 
parallel experiments, we measured cytokine levels in treated 
mice. Murine IL-6 was increased after photothermal therapy 
(Figure 5d). Moreover, human IL-2 and IFN-γ released by CAR 
T cells were also significantly increased, especially in the mice 
receiving the combined treatment (Figure 5e,f).
In summary, mild heating of the tumor triggers physico-
chemical and physiological changes of the tumor, resulting in 
increased infiltration and accumulation of CAR.CSPG4+ T cells. 
In addition to directly killing tumor cells, mild heating can also 
partially destroy tumor cells and extracellular matrix, thereby 
reducing the density of the solid tumor and IFP and expanding 
tumor blood vessels. Moreover, tumor-associated antigens 
released from photothermal therapy may burst endogenous 
immune cells and activate the immune system and potentially 
control metastatic lesions.[10,13] Facilitated by the photothermal 
therapy, CAR.CSPG4+ T lymphocytes traffic to and accumulate 
at the tumor site, following the chemokine and antigen attrac-
tion. In NSG mice engrafted with the human melanoma WM115 
tumors, effective therapeutic effect was achieved after mild 
heating of solid tumors and subsequently intravenous infusion 
of CAR.CSPG4+ T cells. Thus, this strategy provides a prom-
ising platform to increase the therapeutic index of CAR T cells 
in solid tumors simply and safely. It may be further potentiated 
by tuning treatment variables including duration and frequency 
of the photothermal and by including targeted immunomodu-
latory therapeutics.
Experimental Section
Materials, Cell Lines, and Animals: All chemicals were obtained from 
Sigma-Aldrich and used without any purification. Human melanoma 
WM115 cells and WM115-luc cells were obtained from the American 
Type Culture Collection (ATCC) and cultured in RPMI 1640 (HyClon) 
medium containing 10% heat inactivated fetal calf serum (F Invitrogen, 
Carlsbad, CA, USA), 2 mmol L−1 GlutaMAX (Invitrogen), 200 IU mL−1 
penicillin, and 200 mg mL−1 streptomycin (Invitrogen) in an incubator 
at 37 °C in 5% CO2. The CD19-specific CAR T lymphocytes and CSPG4-
specific CAR T lymphocytes also were generated in Dr. Gianpietro Dotti’s 
lab at UNC.[12b] CAR T cells were cultured and expanded in complete 
medium containing 45% RPMI 1640 and 45% Click’s medium (Irvine 
Scientific) with 10% FCS (HyClone), 2 mmol L−1 GlutaMAX, 100 IU mL−1 
penicillin, and 100 mg mL−1 streptomycin. Cells were fed twice a week 
Figure 3. Photothermal therapy of the tumor modifies the tumor microenvironment. a) IR thermal images of WM115-tumor-bearing mice injected with 
PLGA-ICG or PBS with the 808 nm laser irradiation (0.3 W cm−2, 20 min). b) Changes of the tumor temperature measured by the IR thermal imaging. 
c) Immunofluorescence imaging of tumors collected from mice 24 h after photothermal therapy. Scale bar: 50 µm. d) Ultrasound imaging illustrating
the blood perfusion of the WM115 tumors. Microbubbles injected intravenously were used as the ultrasound contrast agent. e) Representative hypoxia 
and HIF1-α immunofluorescence staining of the tumors after photothermal therapy (Scale bar: 50 µm). f) Representative flow cytometry plots and
quantification of murine CD45+ cells infiltrating the tumor after photothermal therapy. Data are presented as mean ± s.e.m. (n = 10). g,h) Representative 
flow cytometry plot and quantification of murine CD11c+ (g) and CD11b+ (h) cells gating on CD45+ cells. Data are presented as mean ± s.e.m. (n = 10). 
i) Quantification of chemokines in the tumor (n = 10). Statistical significance was calculated via two-tailed Student’s t-test. P value: *P < 0.05, **P < 0.01, 
and ***P < 0.001.
with recombinant interleukin-7 (IL-7, 5 ng mL−1; Pepro Tech, Inc.) and 
interleukin-15 (IL-15) (10 ng mL−1; Pepro Tech, Inc.). Female NSG mice 
(6–10 weeks) were purchased from Jackson Lab. All mouse studies were 
carried out following the protocols approved by the Institutional Animal 
Care and Use Committee at the University of North Carolina at Chapel 
Hill and North Carolina State University and complied with all relevant 
ethical regulations.
Synthesis and Characterization of PLGA-ICG Nanoparticles: PLGA-ICG 
nanoparticles were prepared using an o/w single-emulsion method.[10] 
Briefly, photothermal agent ICG was dissolved in DMSO at 10 mg mL−1, 
and then added to PLGA dichloromethane solution. The mixture was 
homogenized with 5% w/v PVA solution by Selecta Sonopuls for 
10 min. Then, the emulsion was added to additional 5% w/v solution 
of PVA to evaporate the organic solvent. PLGA-ICG nanoparticles were 
obtained after centrifugation at 3500 g for 20 min. The morphology of 
PLGA-ICG nanoparticles was characterized by TEM (JEOL 2000FX), 
and the size distribution was measured by the Zetasizer Nano-ZS 
(Malvern Instruments, UK). The absorbance spectrum was recorded by 
Nanodrop.
Cellular Experiments: To study the proliferation of CAR.CSPG4+ 
T lymphocytes, CAR.CSPG4+ T lymphocytes (1 × 106 cells) were stained 
with CFSE (5 × 10−6 m) according to the protocol of the Cell Trace 
CFSE Cell Proliferation Kit (Invitrogen). Then, CAR.CSPG4+ T 
lymphocytes were incubated with PLGA-ICG nanoparticle solution 
after photothermal ablation, WM115 cells or WM115 cells after 
photothermal ablation using a transwell system (400 µm) for 3 days 
in the incubator. The fluorescent intensity of CFSE was detected by 
flow cytometry to monitor the proliferation of T cells. Meanwhile, the 
medium supernatant of CAR.CSPG4+ T lymphocytes was collected and 
cytokines including IL-2 and IFN-γ were measured by an enzyme-linked 
immunosorbent assay.
In Vivo Tumor Models and Treatment: For the in vivo biodistribution 
of CAR.CSPG4+ T lymphocytes, 5 × 106 WM115 human melanoma 
cells were subcutaneously injected into both sides of each mouse. 
After ≈20 days, when the tumor volume reached ≈100 mm3, PLGA-ICG 
nanoparticles were intratumorally injected into the right-side tumors and 
irradiated with an 808 nm laser at the power density of 0.3 W cm−2 for 
20 min. Two hours later, 1 × 107 CAR.CSPG4+ T lymphocytes labeled with 
luciferase were intravenously injected into the mice. At different time 
points after intravenous injection of T cells, mice were imaged via an 
IVIS Spectrum Imaging System (Perkin Elmer Ltd) for 1 min to monitor 
the biodistribution of T cells.
Figure 4. Photothermal ablation of the tumor increases the infiltration of adoptively transferred CAR T cells. a) In vivo bioluminescence imaging of 
the CAR.CSPG4+ T cells. The red arrows indicate the tumor. b) Quantification of CAR.CSPG4+ T cells detected in the tumor with or without photo-
thermal ablation. Data are presented as mean ± s.e.m. (n = 3). c) Representative flow cytometry plots of CAR.CSPG4+ T cells infiltrating the tumor. 
d–f) Absolute frequency of CD3+ (d), CD4+ (e), and CD8+ (f) T cells within tumors. Data are presented as mean ± s.e.m. (n = 4). g) Representative 
immunofluorescence of tumors showing CD4+ and CD8+ CAR T cells infiltrating the tumor. Scale bar: 50 µm. Statistical significance was calculated via 
two-tailed Student’s t-test. P value: *P < 0.05, **P < 0.01, and ***P < 0.001.
For in vivo combination therapy, NSG mice bearing subcutaneous 
fLuc-WM115 tumors were divided into four groups (n = 6 per group): 
(a) untreated, (b) intratumorally injected with PLGA-ICG nanoparticles
and irradiated by the 808 nm laser (0.3 W cm−2, 10 min), (c) intravenously
injected with 1 × 107 CAR.CSPG4+ T lymphocytes only, (d) intratumorally
injected with PLGA-ICG nanoparticles and irradiated by the 808 nm laser (0.3 
W cm−2, 10 min), and then intravenously injected with 1 × 107 CAR.CSPG4+
T lymphocytes. The changes of the temperature on the surface of tumor
were monitored by an IR thermal camera. The tumor sizes were recorded
by a digital caliper every 2 days and calculated according to the following
formula: width2 × length × 0.5. The tumor was also monitored using an in
vivo bioluminescence imaging system. Ten minutes after intraperitoneal
injection of d-luciferin (Thermo Scientific Pierce, 150 mg kg−1) into each
mouse, mice were imaged via an IVIS Spectrum Imaging System for 1 s.
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